Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content. If you have any issues relating to the topics here, please call the MS-UK Helpline on 0800 7830 518.


 

Using a mouse model of human multiple sclerosis (MS), scientists have discovered how T-cells can easily damage the brain.

Inflammatory T-cells in MS are a key group of cells found in the...

The National Institute of Health and Care Excellence (NICE) has announced daclizumab as a cost effective treatment for people with relapsing remitting MS (RRMS). 

NICE has recommended...

A new drug, which has been developed to treat multiple sclerosis (MS), is reportedly being produced by Pharmasyntez and is currently undergoing clinical studies in Russia. According to an official...

Scientists at Queen’s University Belfast have discovered that specific cells from the immune system are key players in brain repair.

The research study, led by Dr Yvonne Dombrowski and Dr...

Apitope, a drug discovery and development company, has revealed ATX-MS-1467 reduced the number and volume of brain lesions with a promising safety profile in relapse remitting MS (RRMS) patients...

Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found...

A therapy that opens up narrowed veins from the brain and spinal cord has been found non-effective in treating multiple sclerosis (MS), according to a study led by the University of British...

Although multiple sclerosis (MS) is thought to be caused by genetic factors, additional environmental elements are increasingly being recognised to have some kind of impact on the onset of the...

New research suggests MS patients who suffer from fatigue and have limited use of their legs...

Positive results from a late-stage clinical trial of ozanimod could make way for another effective multiple sclerosis (MS) treatment. 

In the Celegen clinical trial, dubbed “Sunbeam”, two...

Pages

Live Chat Software by Click4Assistance UK